Product image of Monofree (Dexamethasone Phosphate) supplied by GNH India

Monofree

Active Ingredient:
Dexamethasone Phosphate
Origin:
EU

Monofree (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monofree, is a corticosteroid presented as a sterile ophthalmic solution for ocular use. It is employed to manage inflammatory conditions of the eye, reducing swelling, pain, and immune‑mediated reactions in patients requiring topical therapy.

GNH India supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoires Thea

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Monofree, a corticosteroid, is applied to ocular tissues to control inflammation and immune‑mediated eye disorders.

  • Post‑operative ocular inflammation: reduces swelling and discomfort after eye surgery.
  • Anterior uveitis: diminishes inflammatory cell infiltrate and pain in the anterior chamber.
  • Allergic conjunctivitis: alleviates redness, itching, and edema caused by allergic reactions.
  • Corneal graft rejection: suppresses immune response to improve graft survival.
  • Ocular edema: decreases fluid accumulation in the retina or macula associated with inflammatory processes.

How It Works

  • Dexamethasone phosphate penetrates ocular tissues and binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus. This complex modulates gene transcription, inhibiting pro‑inflammatory cytokines, prostaglandin synthesis, and leukocyte migration, while enhancing anti‑inflammatory protein expression, resulting in reduced ocular inflammation and immune activity.

Side Effects

Adverse reactions may occur with ocular corticosteroid use and should be monitored.

Common Side Effects

  • Transient ocular irritation or burning sensation.
  • Increased intra‑ocular pressure.
  • Blurred vision.
  • Mild cataract formation with prolonged use.
  • Conjunctival hyperemia.

Serious or Rare Side Effects

  • Secondary ocular infection (bacterial or fungal).
  • Glaucoma due to sustained pressure elevation.
  • Delayed wound healing after surgery.
  • Systemic absorption leading to adrenal suppression.
  • Severe hypersensitivity or allergic reaction.

Precautions & Warnings

Monofree requires careful use to minimize risks.

  • Monitor intra‑ocular pressure: check regularly during therapy.
  • Limit duration: use the shortest effective course to avoid cataract formation.
  • Avoid in active ocular infection: corticosteroids can exacerbate infections.
  • Caution in diabetic patients: may affect blood glucose control.
  • Pregnancy and lactation: use only if clearly needed and prescribed.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid)

  • Systemic corticosteroids: additive systemic glucocorticoid effects.
  • Antiviral agents for herpes simplex: may increase risk of viral reactivation.
  • Non‑steroidal anti‑inflammatory eye drops: heightened risk of corneal melting.

Moderate Interactions (Monitor Closely):\n- Anticholinergic ophthalmic drops: may reduce efficacy of dexamethasone.

  • Beta‑blocker eye drops: possible additive effect on intra‑ocular pressure.
  • CYP3A4 inhibitors: may increase systemic exposure if significant absorption occurs.

Frequently Asked Questions

Monofree contains dexamethasone phosphate, a corticosteroid formulated as an ophthalmic solution. It is prescribed to treat inflammatory eye conditions such as post‑operative inflammation, anterior uveitis, allergic conjunctivitis, and ocular edema by reducing swelling, pain, and immune‑mediated responses.

Dexamethasone phosphate enters ocular cells and binds to glucocorticoid receptors. The resulting complex alters gene transcription, suppressing pro‑inflammatory cytokines and mediators while enhancing anti‑inflammatory proteins, which together diminish inflammation and immune activity within eye tissues.

The specific dosing regimen for Monofree is determined by the prescribing ophthalmologist based on the condition being treated, severity, and patient response. The prescriber will provide detailed instructions on the number of drops, frequency, and duration of therapy.

Safety data for dexamethasone phosphate in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the healthcare provider. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their doctor.

To request Monofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Monofree delivers dexamethasone phosphate, a potent corticosteroid with rapid onset of action. Compared with weaker steroids like prednisolone acetate, dexamethasone offers stronger anti‑inflammatory effects, but may carry a higher risk of intra‑ocular pressure rise, requiring closer monitoring.

Monofree should be stored at temperatures below 25 °C, in its original sealed container, protected from moisture and direct sunlight. Do not freeze the solution. Before use, inspect for particulate matter or discoloration and discard if any abnormalities are observed.

Monofree is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Avoid touching the dropper tip to the eye or any surface to maintain sterility.

Serious risks include secondary ocular infections, significant elevation of intra‑ocular pressure leading to glaucoma, delayed wound healing after surgery, and rare systemic effects such as adrenal suppression. Patients should report any worsening vision, pain, or signs of infection promptly.

Monofree should be avoided in patients with active ocular infections, known hypersensitivity to dexamethasone or any formulation component, uncontrolled glaucoma, or those for whom corticosteroid therapy is contraindicated. A healthcare professional must evaluate suitability before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dexamethasone Phosphate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT